

# Erratum: Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma

## Editorial Office

Annals of Translational Medicine

Correspondence to: Editorial Office, Annals of Translational Medicine. Email: editor@atmjournals.org.

Submitted Sep 29, 2024. Accepted for publication Oct 18, 2024. Published online Nov 20, 2024.


doi: 10.21037/atm-2024-41

View this article at: <https://dx.doi.org/10.21037/atm-2024-41>


Erratum to: Ann Transl Med 2021;9:332.

The article (1) titled “Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma” (doi: 10.21037/atm-20-8093) unfortunately contains an error in *Figure 5E*. Two images of *Figure 5E* selected to represent the GAPDH expression in OGD treated PRNs detected by western blotting and *Figure 6K* selected to represent the GAPDH expression in PRNs subjected to OGD detected by western blotting after treatment with the M1 mAChR antagonists were duplicated accidentally. The legend of *Figure 5* should be corrected as well.

*Figure 5E* and *Figure 6K* of the original article:



The correct version of *Figure 5* and its legend are presented below:



**Figure 5** HupA protected against retinal neurons apoptosis induced by I/R and OGD. (A,B) The expression and analysis of apoptosis-related proteins including caspase-3, Bcl-2, and Bax in I/R-induced rat retinal tissue detected by western blot analysis; (C,D) caspase-3 expression and analysis as detected by immunofluorescent staining of rat retinal tissue subjected to I/R treatment; (E,F) the expression and analysis of caspase-3, Bcl-2, and Bax in OGD treated PRNs detected by western blotting. Data are expressed as mean  $\pm$  SEM,  $n \geq 5$  rats or 3 independent experiments. \* $P < 0.05$ , \*\* $P < 0.01$ , compared with the control group; # $P < 0.05$ , ## $P < 0.01$  compared with the OGD group. HupA, huperzine A; I/R, ischemia/reperfusion; OGD, oxygen glucose deprivation; PRN, primary retinal neuron; Pilo, pilocarpine; Phy, physostigmine; Latan, latanoprost; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; OPL, outer platform layer; IPL, inner platform layer; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; SEM, standard error of the mean.

The authors regretted the error and confirmed it did not significantly affect either the results or the conclusions of the paper.

Click [here](#) to view the updated version of the article.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Yu P, Dong WP, Tang YB, et al. Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma. *Ann Transl Med* 2021;9:332.

**Cite this article as:** Editorial Office. Erratum: Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma. *Ann Transl Med* 2024;12(6):126. doi: 10.21037/atm-2024-41